Active Ingredient History
Aflibercept, sold under the brand names Eylea among others, is a medication used to treat wet macular degeneration and metastatic colorectal cancer. It was developed by Regeneron Pharmaceuticals and is approved in the United States and the European Union. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Adenocarcinoma (Phase 2)
Ascites (Phase 2/Phase 3)
Astrocytoma (Phase 2)
Back Injuries (Phase 4)
Biliary Tract Neoplasms (Phase 1)
Body Fluids (Phase 4)
Brain Neoplasms (Phase 2)
Breast Neoplasms (Phase 2)
Carcinoid Tumor (Phase 2)
Carcinoma (Phase 3)
Carcinoma, Non-Small-Cell Lung (Phase 1/Phase 2)
Carcinoma, Renal Cell (Phase 2)
Cataract (Phase 4)
Central Serous Chorioretinopathy (Phase 4)
Choroidal Neovascularization (Phase 3)
Colonic Neoplasms (Phase 2)
Corneal Neovascularization (Phase 1/Phase 2)
Diabetes Mellitus (Phase 4)
Diabetes Mellitus, Type 1 (Phase 2/Phase 3)
Diabetes Mellitus, Type 2 (Phase 2/Phase 3)
Edema (Phase 2)
Endometrial Neoplasms (Phase 2)
Endothelium (Phase 4)
Esophageal Neoplasms (Phase 2)
Eye Diseases (Phase 3)
Fallopian Tube Neoplasms (Phase 2)
General Surgery (Early Phase 1)
Glaucoma (Phase 3)
Glaucoma, Neovascular (Phase 3)
Glioblastoma (Phase 2)
Glioma (Phase 1)
Gliosarcoma (Phase 2)
Graves Ophthalmopathy (Phase 2)
Hemorrhage (Phase 3)
Inflammation (Phase 2)
Leiomyosarcoma (Phase 2)
Leukemia (Phase 2)
Leukemia, Myelomonocytic, Chronic (Phase 2)
Livedoid Vasculopathy (Phase 4)
Liver Neoplasms (Phase 1)
Lung Diseases (Phase 2)
Lung Neoplasms (Phase 2)
Lymphoma (Phase 1)
Lymphoma, Non-Hodgkin (Phase 1)
Macula Lutea (Phase 4)
Macular Degeneration (Phase 4)
Melanoma (Phase 3)
Multiple Endocrine Neoplasia Type 1 (Phase 2)
Multiple Myeloma (Phase 2)
Myelodysplastic Syndromes (Phase 2)
Myeloproliferative Disorders (Phase 2)
Myopia, Degenerative (Phase 3)
Neoplasm Metastasis (Phase 3)
Neoplasms ()
Neovascularization, Pathologic (Phase 4)
Oligodendroglioma (Phase 2)
Optic Nerve (Early Phase 1)
Ovarian Diseases (Phase 2)
Ovarian Neoplasms (Phase 2/Phase 3)
Pain (Phase 1/Phase 2)
Pancreatic Neoplasms (Phase 3)
Polypoidal Choroidal Vasculopathy (Phase 4)
Prostatic Neoplasms (Phase 3)
Pseudoxanthoma Elasticum (Phase 2)
Pterygium (Phase 2)
Rectal Neoplasms (Phase 2)
Retinal Degeneration (Phase 3)
Retinal Detachment (Phase 4)
Retinal Diseases (Phase 4)
Retinal Neovascularization (Phase 2)
Retinal Vein Occlusion (Phase 4)
Retinitis Pigmentosa (Phase 2)
Retinopathy of Prematurity (Phase 3)
Sarcoma (Phase 2)
Small Cell Lung Carcinoma (Phase 3)
Stomach Neoplasms (Phase 2)
Thyroid Neoplasms (Phase 2)
Urethral Neoplasms (Phase 2)
Urinary Bladder Neoplasms (Phase 2)
Uterine Neoplasms (Phase 2)
Vascular Diseases (Phase 4)
Vision, Ocular (Phase 1/Phase 2)
Vitreoretinopathy, Proliferative (Phase 2)
Vitreous Body (Phase 4)
Vitreous Hemorrhage (Phase 2/Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
